GLP-1s, Retatrutide and "Research Use Only" Peptides: What Nurses Need to Know

GLP-1 weight-loss medications are now one of the most requested services in aesthetic practice. Alongside them, a wave of "peptides" is being marketed directly to providers and patients by email, by social media, and by sales reps holding spreadsheets.

Some of these products are FDA-approved drugs. Some are compounded. And some, like retatrutide, are investigational drugs that are not approved for any use. For a nurse, knowing which is which protects your patients and your license.

Approved, Compounded and Investigational Are Not the Same

FDA-approved peptide drugs. More than 40 therapeutic peptides have been approved in the U.S. since 2000, starting with a history that goes back to insulin. Semaglutide and tirzepatide are FDA-approved GLP-1 medications. They are prescription drugs that need a patient-specific prescription.

Compounded versions. The FDA allowed broader compounding of semaglutide and tirzepatide only while they were in shortage. Those shortages have ended, and the FDA now says compounded drugs should only be used in patients whose medical needs can't be met by an FDA-approved drug. The FDA has also reported adverse events, some requiring hospitalization, linked to dosing errors with compounded injectable semaglutide.

Investigational drugs: retatrutide. Retatrutide is still in clinical trials. According to the FDA:

• It is not FDA-approved and is not a component of any FDA-approved drug.
• It cannot be used in compounding under federal law.
• The FDA has sent warning letters to telehealth companies, ingredient distributors and outsourcing facilities over retatrutide.

The FDA sent a letter on compounded retatrutide to the Federation of State Medical Boards. It also shared it with the National Association of Boards of Pharmacy and the National Council of State Boards of Nursing, so your board has received it too.

"Research Use Only" Means Not for Patients

Products labeled "Research Use Only" or "Not for Human Consumption" are raw materials meant for laboratories and enrolled clinical-trial subjects. They are not formulated or validated for human dosing. Giving them to patients outside an authorized clinical trial violates federal law, whatever the product's perceived benefit.

Supplier Red Flags

From the Peptides & Practice course:

• "Physician grade." This marketing term has no legal definition in FDA or state law. Treat it as a reason not to order.
• A 1099 sales rep. Legitimate pharmaceutical companies employ and train their sales staff.
• Ordering from a spreadsheet. FDA-approved drug companies don't sell this way.
• Semaglutide or tirzepatide offered for "in-office use." These need patient-specific prescriptions.
• Missing registration. If a supplier isn't registered with the FDA and your State Board of Pharmacy, don't order.
• Missing label details. Legitimate labels show the manufacturer or compounding pharmacy, lot number, expiration date, strength, and patient-specific details where required.

Enforcement Is Real

• Utah, April 2026. A federal grand jury indicted a Utah physician who allegedly obtained peptides from China and sold them to more than 200 patients. The products included tirzepatide, semaglutide, retatrutide and BPC-157. An indictment is an allegation, not a finding of guilt.
• Ohio. The Ohio Board of Pharmacy has issued summary suspensions against clinics and distributors where unapproved peptides were found.

How to Check Before You Order

• Classify the product: FDA-approved drug, compounded drug, or unapproved peptide.
• Search the FDA drug database and your State Board of Pharmacy lookup.
• Confirm the supplier's registration before placing an order.
• Make sure there's a valid, patient-specific prescription after an appropriate exam by a qualified prescriber.

Learn More: Peptides & Practice (2 Contact Hours)

Peptides & Practice covers peptide fundamentals and the difference between drug and biologic classifications. It also covers common non-FDA-approved peptides and what the research shows, FDA bulk-substance categories and compounding rules, research-product law, supplier red flags, and decreasing implicit bias. Presented by Cynthia Vokey, RN. California BRN Provider #18009.

Need written peptide and GLP-1 policies for your practice? Aesthetic Nursing Policy & Procedures builds practice-specific manuals. Visit AestheticNursingPnP.com

Educational information only, not legal advice. Requirements vary by state; confirm with your state board.

Sources

• [FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)
• [FDA letter to FSMB on compounded retatrutide](https://www.fsmb.org/siteassets/communications/retatrutide-letter-to-fsmb.pdf)
• [U.S. Attorney's Office, District of Utah (April 1, 2026)](https://www.justice.gov/usao-ut/pr/utah-licensed-osteopathic-physician-indicted-allegedly-receiving-misbranded-drugs-china)
• [Frier Levitt, Peptides Under the Microscope (Ohio enforcement)](https://www.frierlevitt.com/articles/injectable-peptides-fda-state-enforcement-compounding/)